AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03190746 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TaqMan SNP analysis
Description: TaqMan SNP analysis of the YWHAH gene
Study NCT04107987 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reglicem
Description: Reglicem is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate
Study NCT04107987 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00698945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Istalol and Optive
Description: Istalol: one drop a day for 28 days Optive: one drop a day for 28 days
Study NCT00698945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alphagan
Description: Alphagan: two drops a day for 28 days
Study NCT00607685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil with hyaluronic acid
Description: Participants will receive a subconjunctival injection of 0.1ml of a mixure of 5 Fluorouracil (50mg/ml) with hyaluronic acid (23mg/ml) once at enrollment into the study.
Study NCT00607685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 Fluorouracil
Description: Pariticpants will receive a subconjunctival injection of 0.1ml of 5 Fluorouracil 50mg/ml once at enrollment
Study NCT05180929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual M1-tDCS
Description: In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.
Study NCT05180929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a-tDCS over contralesional PMC
Description: In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region
Study NCT05180929 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
Study NCT03382379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial Direct Current Stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak (2 mAmp) direct current over the skull for 1200 seconds with 30 seconds ramp up to 2 mAmp, and 30 seconds ramp down at the end.
Study NCT03382379 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham transcranial Direct Current Stimulation (tDCS)
Description: Sham Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak direct current over the skull. Sham mode will have just 30 seconds ramp up to 2 mAmp, 40 seconds on 2 mAmp stimulation and, 30 seconds ramp down with 1160 seconds no stimulation (just impedance control).
Study NCT01877837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Adjusted Ideal Body Weight Formula: AIBW = IBW + \[(0.4) x (ABW - IBW)\]~b) Medications~i.) Alemtuzumab I. Hb S% must be \< or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued >48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below
Study NCT01877837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine
Study NCT01877837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. \*Entire dose must be infused within 60 minutes of reconstitution in Pharmacy.~II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion.
Study NCT01877837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: Infusion of Hematopoietic Stem Cells
Study NCT00153881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda)
Description: Neoadjuvant Chemotherapy:~Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.~Concomitant chemotherapy and radiation:~Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles).
Study NCT00872677 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diet
Description: Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
Study NCT00872677 — intervention group
Intervention type: OTHER
Intervention: Spiritual counseling
Description: Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
Study NCT01900197 — intervention group
Intervention type: DRUG
Intervention: 10% Iron Isomaltoside 1000
Description: Administered according to local routines and product labeling in doses at the doctors discretion
Study NCT01458431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: continuous levobupivacaine subfascial infusion
Study NCT01458431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: continuous NaCl subfascial infusion
Study NCT00423943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: 200 milligrams daily dose
Study NCT00423943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: capsule containing placebo
Study NCT03980600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibDex wound dressing
Description: Treatment of donor sites of 24 patients with the dressing Type 4 (final product i.e. FibDex) until the self-detachment of the wound dressing i.e. epithelialization
Study NCT03980600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NFC wound dressing Types 1-3
Description: Treatment of donor sites of 9 patients with the NFC dressing's (proto)Types 1-3 until the self-detachment of the wound dressing i.e. epithelialization
Study NCT03980600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprathel (comparator)
Description: Treatment of donor sites of 22 patients with Suprathel dressing, which was used as a reference (comparator) product, until the self-detachment of the wound dressing i.e. epithelialization
Study NCT03611413 — intervention group
Intervention type: PROCEDURE
Intervention: ERAS care
Description: ERAS PROTOCOL
Study NCT02590705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: surface anesthesia with lidocaine
Study NCT01458639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenon-133 Ventilation Planar imaging
Description: Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
Study NCT04388683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (day 1), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM.
Study NCT03960216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Patients received non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia.
Study NCT03960216 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Supragingival Prophylaxis
Description: Supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart.
Study NCT00294203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa group
Description: Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
Study NCT00294203 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
Study NCT01299870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AED treatment plus placebo
Description: Your usual AED(s) treatment with placebo for 12 weeks followed by 4 weeks washout period, and then Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) treatment for 12 weeks.
Study NCT01299870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keishibukuryogan
Description: Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) for 12 weeks followed by 4 weeks washout period, and then your usual AED(s) treatment with placebo for 12 weeks.
Study NCT05255575 — intervention group
Intervention type: DRUG
Intervention: Ertapenem
Description: Patients will receive ertapenem therapy.
Study NCT04072042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib monotherapy
Description: patients will receive Apatinib 250mg tablet by mouth, bid.
Study NCT02416843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of a mixed meal
Description: Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.
Study NCT04397991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Patients will receive nebulised furosemide solution 1 mg/kg
Study NCT04397991 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive nebulised 0.9% saline
Study NCT00433940 — intervention group
Intervention type: DRUG
Intervention: Prednisolone
Description: Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
Study NCT00852033 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Intervention (BMI)
Description: Students met with trained interventionists. The initial BMI took place during the fall semester of the freshmen year for approximately 45 minutes. Individualized feedback was used to guide the BMI sessions. The feedback data were gathered through an online survey completed within two weeks of the scheduled appointment to ensure the use of proximal feedback reflecting current drinking. Feedback was tailored so that drinkers received information on their personal drinking patterns, heavy episodic drinking, and alcohol-related consequences, and abstainers received feedback on their perceived barriers for maintaining abstinence, the safety and health benefits of their choice not to drink, and their experience with second-hand effects of alcohol use. In the spring of the freshmen year, students received a BMI 'booster' session. Individualized feedback was created from the original online survey and the 10 month follow-up assessment.
Study NCT02859259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068 (1 tablet at 600 mg)
Description: BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.
Study NCT02859259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068 (4 tablets at 150 mg each tablet)
Description: BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.
Study NCT03056417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Complete Health Improvement Program
Description: The Complete Health Improvement Program is a nationally recognized program that encourages a diet of whole plant based foods, moderate exercise, stress reduction, and social support.
Study NCT05448339 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: PVHA or TACE
Description: PVHA or TACE
Study NCT00852033 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Based Intervention plus booster
Description: The PBI is a handbook-based intervention modified from Turrisi and colleagues (2001). It was designed to raise parental awareness of alcohol abuse and consequences among college students and increase parental effort to address this issue with their teen.
Study NCT03883581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan HBr and quinidine sulfate
Description: All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
Study NCT01919944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLY-686
Description: capsules containing either 10 mg or 50 mg VLY-686
Study NCT01919944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
Study NCT01919944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
Study NCT04562181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bispectral index and qCON/qNOX monitoring
Description: This study will characterise the bispectral index data and qCON/qNOX index data in 30 patients during the operation and first postoperative night
Study NCT00877240 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff
Description: the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop
Study NCT02362321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
Study NCT02362321 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
Study NCT03951077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Capsule administered orally
Study NCT00852033 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined brief motivational intervention and parent based intervention plus boosters for both interventions
Description: A combination of Intervention 1 and 2.
Study NCT00852033 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Assessment only
Description: No intervention, assessment only.
Study NCT03299998 — intervention group
Intervention type: PROCEDURE
Intervention: Maxillary and mandibular blocks
Description: A Pajunk SonoPlex Stim needle 22G x 55 mm was used. For maxillary nerve block, needle was introduced next to the angle of the orbitae and the zygomatic ridge. The needle was sank until coming into contact of the temporal bone. It was then orientated to the controlateral nostril and sank of 1 cm. For mandibular block, needle was introduced in the pterygoid fossa under and perpendicularly to the zygomatic arch, and sank until the pterygoid process. The needle was then orientated towards controlateral orbitae and sank with neurostimulation. After a motor response at 0.6 milliampere (mA) and the disappearance of contraction at 0.3 mA, local mixture was injected. The mixing of local anesthesia was made of ropivacaine 5 mg/mL and clonidine 30 µg. Five mL were injected in every block for a total of 20 mL.
Study NCT03299998 — intervention group
Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Anesthesia was standardized and provided using intravenous administration of propofol and remifentanil. Patients were mechanically ventilated with a mixture of air (50/50), and desflurane or sevoflurane, or Target-controlled infusion (TCI) propofol. One to 5 mg/kg of methyl-prednisolone were administered to reduce inflammatory response.
Study NCT02982460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isoinertial + eccentric exercise
Description: A session of isionertial + eccentric exercise covers the activity, strength and endurance of scapular muscles.
Study NCT02982460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise
Description: A session of eccentric exercise covers the strength of scapular muscles.
Study NCT04973501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual physiotherapeutic correction (MFK) Method
Description: Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
Study NCT04973501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Neuromuscular Stabilization (DNS) Method
Description: Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total).Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
Study NCT02366468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5 mg
Description: intravitreal injection
Study NCT02366468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab 0.5 mg
Description: intravitreal injection
Study NCT03584542 — intervention group
Intervention type: OTHER
Intervention: No interventional study
Description: No Interventional study - Only one questionnaire will be done for patients and for general practitioners
Study NCT05212805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Interventions will be delivered through twenty supervised 40-minutes aerobic sessions (3 times a week). Patients will be trained on a bicycle ergometer (5-minute warm-up, 30 minute of intense training, 5-minute cool-down). Warm-up will be performed at the 30% of the maximal heart rate, while training will be performed at the 50-70% of the maximal heart rate as recommended by the general guidelines for aerobic exercise training specific for MS. Actual heart rate will be constantly monitored by a wearable heart rate monitor.
Study NCT05212805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-oriented upper-limb training
Description: The training will consist in twenty 1-hour sessions (3 times a week) of exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, including unimanual and bimanual task-oriented exercises.
Study NCT05212805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task-oriented upper-limb training
Description: The training will consist in twenty 1-hour sessions (3 times a week) of exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, including unimanual and bimanual task-oriented exercises.
Study NCT05212805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sport events participation
Description: A subgroup of participants will also be involved in events promoting sports activity including both aerobic and task-oriented exercises (e.g., water sports such as sailing, windsurfing, canoeing) in order to evaluate their potential role to increase adherence to training, participation and quality of life.